Category
Androgen Receptor Antagonist
Generic Name
Enzalutamide
Formulation
Each softgel capsule contains 40mg enzalutamide
Indication
-
For the treatment of adult men with metastatic castration-resistant prostate cancer who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated
- For the treatment of adult men with metastatic castration-resistant prostate cancer whose disease has progressed on or after docetaxel therapy.
Dosage
The recommended dose is 160 mg Enzalutamide (Xtandi®) (four 40 mg capsules) as a single oral daily dose.
Contraindication
Hypersensitivity to enzalutamide or to any of its excipients.
Women who are or may become pregnant.
Packaging
Box of 112’s softgel capsules (4 capsule per pouch)